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Abstract 
The outcome of the patients with newly 
diagnosed glioblastoma remains dismal, 
despite the use of surgery, radiotherapy and 
adjuvant temozolomide and while new 
agents like anti-angiogenic agents seem to 
offer some promise, a new approach is 
needed. Recent studies suggest that cancer 
stem cells (CSCs) may play an important 
role in malignant gliomas invasion and 
proliferation. Therefore, CSCs became new 
therapeutical targets, and one of the main 
experimental therapies which could be used 
against CSCs is the differentiation therapy. 
The purpose of this study was to 
characterize the CSCs isolated from 
glioblastoma samples, to assess in vivo the 
tumorigenic potential of these cells and to 
induct the differentiation of the CSCs. The 
changes in invasive markers 
(matrixmetalloproteases-MMPs, cadherins 
and cathenins) expression were assessed. 
CSCs exposed to differentiation inductor 
factors have been inoculated in nude mice 
and their tumorigenic potential has been 
evaluated. The stemness biological feature 
was correlated with increased of MMPs, 
cadherins, catenin expression and with 
tumour contra-lateral invasion. The 
expression of MMPs, cadherins and 
cadherins decreased after exposure of the 
CSCs cultures to the differentiation 
inductor factors. In vivo experiments 
demonstrated the inhibition of tumorigenic 
potential of differentiated CSCs cultures. 
In conclusion, differentiated CSCs 
showed a decreased expression of invasive 
markers in vitro and lost their tumorigenic 
potential in vivo. 
Keywords: glioblastoma, cancer stem 
cells, xenografts, differentiation therapy. 
Introduction 
Malignant brain tumors remain severe 
diseases with a dismal prognosis despite the 
modern multimodal therapeutically 
management (5). For example in 
glioblastoma, the mortality is 100% and the 
medium period survival is approximately 12 
months (27).  
Embryonic stem cells could suffer 
several genetic mutations during specific 
proliferation phase of ontogenesis (12). 
These genetic mutations could lead to early 
development of various types of cancer 
early during childhood (8). Conversely, the 
adult stem cells could bear specific genetic 
mutation, and they can transform into 
cancer stem cells which secondary lead to 
oncogenesis (13). 
Isolation and characterization of cancer 
stem cells (CSCs) from human 
 
 
 
426          F.M. Brehar et al          Inhibition of tumorigenic potential in glioblastoma 
 
 
 
glioblastoma opened new opportunities in 
glioblastoma research and could offered 
alternative therapies for this severe disease 
(16; 14).  
The cancer stem cells theory proposes 
that transformed neural stem cells could be 
the origin of gliomas (10). In adult brain, 
neural stem cells are located mainly in two 
important regions: hippocampus and 
periventricular region.  
Adult human subventricular zone of 
brain is composed of several important 
layers: deep subcortical white matter, a 
periventricular ribbon of cells that can 
function as neural stem cells, a dense layer 
of astrocytic processes and the ependymal 
lining. Astrocytes from the subventricular 
zone exhibit a unique capacity for 
multipotency and self-renewal in vitro. The 
cancer stem cells theory proposed that 
tumoral transformation of the neural stem 
cells occurring at the periventricular zone, 
followed by migration of these transformed 
cells throughout brain parenchyma could 
be at the origins of gliomas (10). 
Recent studies demonstrated that CSCs 
represent a very important tumor cell 
population, responsible for 
chemotherapeutic and radiotherapeutic 
resistance, because these cells secrete multi 
drug resistance proteins (like Breast Cancer 
Resistance Protein-1 (BCRP1) (6). 
Therefore CSCs become now one of the 
main attractive therapeutically targets 
within the multimodal management of 
glioblastoma (1). 
According to Vescovi et al., induction of 
differentiation of CSCs, using BMP-4 
molecule, is able to inhibit the tumorigenic 
potential of these cells (15). This strategy, 
called differentiation therapy, which has 
been initially used in malignant 
hemophaties (9; 11; 21) could represent in 
the future an important alternative therapy 
for glioblastoma.  
The purpose of this study was to assess 
in vitro the expression of invasive 
molecules like MMPs and in vivo the 
tumorigenic potential of the CSCs after 
exposing the CSCs cultures to 
differentiation inductor factors. 
Materials and methods  
Cell cultures 
Tumors from patients with confirmed 
glioblastoma multiforme (GBM) were 
mechanically and enzymatically dissociated 
and grown in neural stem cell expansion 
medium to generate neurospheres (DMEM 
supplemented with 10-20ng/ml FGF; 10-20 
ng /ml EGF; 1x B27; 1xN2). U87 line was 
purchased from the European Collection of 
Animal Cell Cultures (ECACC No. 
89081402).  
Flow cytometry 
5 X 105 cells were collected, washed 
twice in PBS, 0.1% BSA, and then cells 
were incubated for 1 h with monoclonal 
antibody CD133/2-PE, CD 45 (Miltenyi 
Biotec, Germany), O4 and A2B5. The 
labeled cells were analyzed using a 
Beckman Coulter EPICS XL flow 
cytometer. Ten thousand events were 
acquired and data were analyzed with 
FlowJo software. Positive cells were 
determined as percentages of gated cells. 
Microarray experiments 
Microarray analysis was performed using 
Agilent technology according to One-Color 
Microarray- Based Gene Expression 
Analysis, version 5.5 / february 2007. We 
used microarray slides Whole Human 
Genome Oligo Microarray with SurePrint 
Technology 4 x 44 K. The changes in the 
expression level of MMPs, cadherins and 
cathenins have been assessed.  
Induction of differentiation of CSCs 
Glioblastoma derived CSCs cultures 
where exposed to DMEM supplemented 
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with fetal serum (10%) and several known 
differentiation inductor factors like BDNF, 
NT3 and all-trans retinoic acid (ATRA) 
which is known as a potent inductor of 
differentiation of cellular precursor in 
several malignant hemopathies (26), at 
different concentration levels. The effects 
of differentiation of CSCs were assessed in 
vitro, by evaluating the morphology of 
CSCs cultures and microarray expression of 
invasive markers. CSCs exposed to the 
differentiation factors have been inoculated 
in nude mice and their tumorigenic 
potential has been assessed. 
In vivo tumor model 
Three groups including 24 nude mice, 
8–10-weeks-old (Crl: CD-1-Foxn1nu; 
Charles River Breeding Laboratories, 
Germany) were used in experiments. 
Animals were anesthetized by 
intraperitoneal injection of xylazine and 
ketamine. Mice were held in a stereotactic 
frame with ear bars (TAXIC-600, World 
Precision Instruments) and received 
stereotactically guided injections over 3 min 
into right forebrain. First group of eight 
animals received 5 x 105 cells of U87 
culture in a volume of 3 μl PBS. The 
second group of eight animals received 2 x 
105 cells of glioblastoma derived CSCs 
culture in a volume of 3 μl PBS. The 
growth pattern of glioblastoma CSCs 
xenografts were compared with U87 
xenografts. In order to assess the effects of 
differentiation of CSCs, glioblastoma 
derived CSCs cultures exposed to fetal 
serum (10%) + differentiation inductor 
factors have been inoculated (2 x 105 cells) 
in the third group of 8 mice. All the surgical 
and experimental procedures involving 
animals were approved by the Institutional 
Animal Care and Use Committee, in 
accordance with Romanian governmental 
guidelines for ethics in animal experiments.  
 
Histology 
Mice bearing intracranial human 
glioblastoma xenografts were sacrificed at 
21 and 28 days (first group) and at two 
months (second and third group) after cells 
implantation. Brains were removed and 
were fixed in Bouin solution or 4% 
paraformaldehide in PBS, dehydrated in 
ethanol, cleared in toluene and embedded 
in paraffin. About 6 m-thick horizontal 
sections were used for hematoxylin and 
eosin (H&E) staining. The 
photomicrographs were taken by digital 
camera (AxioCam MRc 5, Carl Zeiss) 
driven by software Axio-Vision 4.6 (Carl 
Zeiss). 
Results 
In vitro results 
We initiated several primary cultures 
from glioblastoma samples using special 
medium for neural stem cells cultures. The 
medium was changed every 3 days. Cells 
survived in cultures but the proliferation 
rate was low. The cells in the cultures 
organized in clusters similar to 
neurospheres, which are the morphological 
hallmarks of neural stem cells (Figure 1 A, 
B). 
Cells cultures obtained from malignant 
gliomas samples expressed stem cells and 
oligodendrocyte markers at different levels 
(Table 1). However, all cultures expressed 
neural stem cells markers (especially 
CD133) at higher levels compared with 
U87 line (Table 1, Figure 2). 
In vivo results 
U87 developed intracranial xenografts 
with a specific growth pattern. The U87 
xenografts were compact, round-shape, 
with no sign of infiltration of surrounding 
brain parenchyma (Figure 3 A, B). The size 
of the xenografts was in accordance with 
literature data.  
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At 28 days the U87 xenografts were 
voluminous, occupying more then a half of 
cerebral hemisphere (Figure 3B), which 
appeared bulge and expanded at 
macroscopic examination. The detailed 
growth pattern of U87 xenografts has been 
described elsewhere by the authors (7, 24). 
 
 
A 
 
B 
Figure 1 A, B Neurospheres in glioblastoma derived 
cells cultures grown in special stem media: DMEM: 
F12 supplemented with 10 ng/ml FGF, 20 ng/ml 
EGF,  N2, B27, at 370C  (Ob 20X) 
 
TABLE 1 
Expression of neural stem cells markers 
(CD133, O4) and oligodendrocyte markers 
(A2B5, O4) in cells cultures 
Culture CD133 O4 A2B5 
U87 2,56 5,51 20,24 
STON 39,57 2,09 13,97 
FAIO 10 29,82 3,84 70,38 
BARB8 12,25 0,86 12,56 
 
 
 
 
 
 
 
Figure 2 Expression of stem cells markers CD 133, 
CD 45 and O4 in cells cultures 
Barb 
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Figure 3 U87 xenograft at 21 days (a) and 28 days 
alter inoculation. H&E staining 
 
The glioblastoma derived CSCs induced 
xenografts with a different growth pattern. 
Unlike U 87 xenograts, the CSCs 
xenografts exhibits a more infiltrating 
pattern (Figure 4). 
 
 
 
Figure 4 CSCs xenograft infiltrating the corpus 
callosum (arrow) in one specimen (a). Voluminous 
CSCs xenograft which infiltrates the opposite 
emisphere through the corpus callosum, in another 
specimen (b). H&E staining 
 
Interestingly, migratory tumor cells were 
found at distance from the CSCs 
xenografts, infiltrating surrounding brain 
parenchyma (Figure 5 A) or even the white 
commissural fibers (Figure 5 B). 
Induction of differentiation of CSCs – results 
Important changes in cultures 
phenotype has been noticed at approximate 
24-48 hours after exposure of the cells 
cultures to fetal serum and differentiation 
inductor factors. Tumor cells lost their 
ability to form neurospheres and acquired a 
fibroblastic phenotype very similar to the 
morphology of standard glioblastoma lines 
(Figure 6). 
The CSCs cultures express MMPs, 
cadherins  and cathenins  at higher level (up 
to ten times) compared with the fibroblastic 
aspect of the same cultures after exposure to 
the differentiation inductor factors 
(microarray studies) (Figure 7). 
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Figure 5 Tumor cells located near the CSCs 
xenograft (arrows) infiltrating the hippocampus (a). 
Migratory tumor cells (arrows) distant located from 
the CSCs xenografts, in corpus callosum, migrating 
to the opposite hemisphere (b). H&E staining 
 
 
Figure 6 The fibroblastic phenotype of the CSCs 
after exposure of the cells cultures to the 
differentiation inductor factors 
 
Figure 7 MMPs (purple), cadherin (blue) and 
cathenins (red) expression in CSCs cultures before 
and after exposure of the cell cultures to the 
differentiation inductor factors 
Discussions 
Initiation of CSCs cultures 
We observed formation of cells clusters 
similar to neurospheres at approximately 
14-21 days after initiation (Figure 1 A, B). 
Neurospheres could be passaged multiple 
times by mechanical dissociation of large 
spheres and reseeding in fresh proliferative 
medium every 2–3 weeks. Some of the 
initiated cultures formed the free-floating 
structures generated by these cells in vitro, 
the "neurospheres", considered to be a 
characteristic feature of tumor neural stem 
cell, which were morphologically and 
functionally heterogeneous.  
The expression of neural stem cells 
markers (CD133, O4) were assessed by 
flow-cytometry analysis. All the newly 
initiated cultures expressed high level of 
neural stem cells markers compared with 
U87 cultures (Table1, Figure 2). Among 
several markers considered to be specific for 
neural stem cell and CSCs isolated from 
glioblastoma, CD 133 was the first and the 
most used (17, 23). Despite of several 
published evidence that identified 
glioblastoma derived CSCs population 
negative for CD 133 (3, 20), this marker 
remain one of the most used for identifying 
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glioblastoma derived CSCs. Our 
glioblastoma derived cultures cells 
expressed high level of CD133 compared 
with U87, indicating the presence of a large 
population of CSCs cells. The using of 
serum-free culture (neurosphere assay) 
allowed the selection of CSCs containing 
subpopulation that were able to reproduce 
original tumor aspect in orthotropic 
xenografts. 
CSCs xenografts 
CSCs xenografts exhibit specific growth 
pattern, very different from the compact 
growth pattern of the U87 xenografts. At 
two months after inoculation, CSCs induce 
usually smaller xenografts (Figure 4 A) 
compared with 28 days U87 xenografts 
(Figure 3 B), but with more extensive 
infiltrating pattern. However there were 
also CSCs xenografts with a volume 
comparable with U87 xenografts (Figure 4 
B). U87 xenografts have a compact growth 
pattern with no obvious signs of brain 
infiltration. Even if the xenografts reached 
considerable volume, tumor developed only 
in the ipsilateral cerebral hemisphere, at the 
inoculation area. In contrast with the U87 
xenografts, CSCs xenografts were highly 
infiltrating. The final behaviour was to 
infiltrate the opposite cerebral hemisphere, 
through the corpus callosum or dorsal 
hippocampal comissure (Figure 4 A, B). 
This infiltrating growth pattern seems to be 
specific not only for glioblastoma but also 
for anaplastic astrocytoma derived CSCs 
xenografts (4). When higher magnification 
was used, we could notice tumor cells with 
migratory features infiltrating not only the 
surrounding brain parenchyma, but also the 
white commissural tracts, explaining the 
infiltration of the tumor into the opposite 
hemisphere. These findings, which suggest 
that CSCs could drive the invasive 
phenotype of malignant gliomas, are 
supported also by the in vitro results. CSCs 
cultures expressed at higher levels (up to 
ten times) MMPs and cadherins, compared 
with the differentiated cells cultures (Figure 
7). MMPs and cadherins are important 
markers associated with cells invasion; 
therefore the high expression of these 
molecules could explain the infiltrating 
growth pattern of the CSCs xenografts. 
According to Beadler et al., the infiltrating 
glioblastoma cells and migratory precursor 
neural cells used the same molecular 
mechanisms (2). One of the main 
molecular mechanisms is the LIS-1/dynein 
complex (18). This molecular mechanism 
could be used also by glioblastoma derived 
CSCs. On the other hand, according to our 
previously reports, there are also other 
molecular markers potentially involved in 
CSCs migration, like VCAM-1, which 
could explain the high migratory feature of 
malignant gliomas CSCs xenografts (25). 
Induction of differentiation 
In order to see how the differentiation of 
CSCs will influence the expression of 
invasive markers and their tumorigenic 
potential, CSCs cultures were exposed to a 
combination of fetal serum (10%) and 
differentiation factors like BDNF, NT 3 
and ATRA. The first change to be noticed 
was in the morphology of the cells. Thus, 
the neurospheres become smaller and 
eventually disappeared in 24-48 hours, and 
the cells exhibited a fibroblastic phenotype 
and adhered to the bottom of the culture 
dish (Figure 6). The expression of MMPs, 
cadherins and cathenins, evaluated by 
microarray experiments, decreased after 
exposure of the CSCs cultures to the 
differentiation inductor factors (Figure 7). 
Important to mention that in vitro changes 
was noticed only when the differentiation 
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factors (BDNF, NT3 and ATRA) were 
used together with fetal serum. 
Differentiated CSCs with fibroblastic 
phenotype were not been able to induce the 
formation of tumor xenografts in mice 
brain. Therefore in vivo experiments 
demonstrated the inhibition of tumorigenic 
potential of CSCs cultures exposed to the 
differentiation factors. 
MMPs and cadherins are key molecules 
involved in tumor invasion (19; 22). The 
marked decreased in the MMPs and 
cadherins expression after exposure to the 
differentiation factors could explain the lost 
of tumorigenic potential of cells cultures.  
These findings suggest that 
differentiation therapy, which target CSCs, 
could be successfully applied in 
glioblastoma. However, these are only 
preliminary results and further studies are 
needed in order to find the optimal 
combination of molecules able to induct a 
strong and irreversible differentiation of 
CSCs and to block the proliferation and 
invasion of malignant gliomas cells.  
Conclusions  
Serum-free culture allowed the selection 
of a subpopulation containing CSCs with 
increased tumorigenic potential. When 
exposed to a specific combination of 
differentiation inductor factors, CSCs 
cultures showed a marked decrease of 
expression of invasive markers (MMPs and 
cadherins) and lost their tumorigenic 
potential. Our findings confirm the 
potential of differentiation therapy as a 
novel experimental therapy for infiltrative 
glioblastoma and further studies should be 
performed in order to assess the clinical 
potential of differentiation inductor 
molecules as a novel therapeutically agents 
in glioblastoma. 
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